A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease

Current Medicinal Chemistry
Jan KorabecnyOndrej Soukup

Abstract

Alzheimer's Disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden. This review presents the overview of donepezilrelated compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.

References

Jan 1, 1990·Journal of Pharmaceutical Sciences·J NishijoM Sugiura
Feb 1, 1974·Archives of Neurology·D A Drachman, J Leavitt
Aug 19, 1994·Journal of Medicinal Chemistry·A VillalobosA A Nagel
Dec 24, 1997·Annals of Neurology·A L GuillozetM M Mesulam
Mar 3, 1999·Journal of Medicinal Chemistry·J M ContrerasC G Wermuth
Dec 28, 1999·Bioorganic & Medicinal Chemistry Letters·F ZengR Ji
Jun 27, 2002·Japanese Journal of Pharmacology·Hachiro SugimotoYoshiharu Yamanishi
Aug 17, 2002·Bioorganic & Medicinal Chemistry Letters·John K ClarkMing-Qiang Zhang
Nov 3, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·S K SonkusareP Ramarao
Jul 5, 2005·Bioorganic & Medicinal Chemistry Letters·Rong ShengYongzhou Hu
Sep 3, 2005·European Journal of Medicinal Chemistry·Ziad OmranSylvain Rault
Sep 27, 2005·Bioorganic & Medicinal Chemistry·María Isabel Rodríguez-FrancoAna Martínez
Oct 27, 2005·Journal of Agricultural and Food Chemistry·Hee KimSung-Eun Lee
May 25, 2006·The Journal of Neuropsychiatry and Clinical Neurosciences·Xiying ChenSusan K Schultz
Jun 15, 2006·Alzheimer Disease and Associated Disorders·Agneta Nordberg
Jul 24, 2007·Biochemical and Biophysical Research Communications·Masahiro OnoMorio Nakayama
Sep 11, 2007·Bioorganic & Medicinal Chemistry·Masahiro OnoMorio Nakayama
Jan 22, 2008·The FEBS Journal·Nibaldo C InestrosaAlejandra Alvarez
Apr 26, 2008·European Journal of Medicinal Chemistry·Rong ShengYongzhou Hu
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Abraham Fisher

❮ Previous
Next ❯

Citations

Mar 2, 2019·Current Alzheimer Research·Martina KaniakovaMartin Horak
May 18, 2019·Journal of Biomolecular Structure & Dynamics·Srishti SharmaKallol K Ghosh
Sep 6, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Giambattista MarottaAnna Minarini
Jan 5, 2021·Aging Medicine·Chuyao WangTao Li
Oct 19, 2020·Toxicology and Applied Pharmacology·Md NematullahFarah Khan
Dec 29, 2019·The Journal of Physical Chemistry. B·Sai Vamshi R JonnalagaddaManos Gkikas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Related Papers

Brain and nerve = Shinkei kenkyū no shinpo
Shunichiro Shinagawa, Masahiro Shigeta
Ceská a Slovenská farmacie : casopis Ceské farmaceutické spolecnosti a Slovenské farmaceutické spolecnosti
Jan KorabecnyKamil Kuca
Current Medicinal Chemistry
V TumiattiC Melchiorre
© 2022 Meta ULC. All rights reserved